Topical Pranoprofen 0.1% Is As Effective Anti-Inflammatory and Analgesic Agent as Diclofenac Sodium 0.1% After Strabismus Surgery

Abstract

To compare the anti-inflammatory and analgesic effects of topical pranoprofen 0.1% with diclofenac sodium 0.1% after strabismus surgery, 40 patients were prospectively randomized and assigned into 2 groups. Signs and symptoms of inflammation, as well as intraocular pressure (IOP) of patients, were evaluated at 1 day and 1 and 3 weeks following surgery. Both groups reported reduced inflammation and discomfort at 1 week, as compared to 1 day. There was no statistically significant difference in any measurement of postoperative inflammation (i.e., discomfort, chemosis, secretion, conjunctival hyperemia, and conjunctival gap size) between the 2 groups at any time. None of the patients developed an allergic reaction to the medications and IOP measurements were within the normal limits in both groups. Pranoprofen 0.1% was found to be as effective as diclofenac sodium 0.1% in reducing inflammation and pain after strabismus surgery. Pranoprofen could be used as a safe and effective anti-inflammatory alternative for the treatment of inflammation following strabismus surgery.

Topical Ocular Delivery of NSAIDs

“…Topically applied pranoprofen has been demonstrated to possess analgesic and ocular anti-inflammatory activity comparable to flurbiprofen in endotoxin-induced uveitis model (86). It has also been found to be as effective as diclofenac sodium(0.1%, wt/vol) in reducing pain and inflammation after strabismus surgery (87).…”

Design of Nanosuspensions and Freeze-Dried PLGA Nanoparticles as a Novel Approach for Ophthalmic Delivery of Pranoprofen

“…Pranoprofen (PF) is a nonsteroidal anti-inflammatory drug that can be used as a safe and effective alternative antiinflammatory treatment following strabismus and cataract surgery. [1][2][3] PF has the beneficial effect of reducing the ocular signs and symptoms of dry eye and decreasing the inflammatory markers of conjunctival epithelial cells. 4 Its efficacy is equivalent to moderate-potency corticosteroids, but it has a better safety profile.…”

Dose dependent cytotoxicity of pranoprofen in cultured human corneal endothelial cells by inducing apoptosis

“…Non-steroidal anti-inflammatory drugs (NSAIDs) which can eliminate inflammation in cornea by controlling the secretion of prostaglandin are often used in keratitis treatment in eye clinic. Amongst NSAIDs, pranoprofen (PPF), as a kind of propanoic acid with both hydrophilic and hydrophobic properties, is often used clinically in therapy of inflammation in the exterior and anterior segments of the eye (Akyol-Salman et al, 2007;Qu et al, 2011;Zhao et al, 2000). At the same time, there have also been reports on side effects of PPF, including irritation, conjunctival congestion, itching, and palpebral edema (Zhu et al, 2009).…”